Condition
Diabetes Mellitus, Type 2
Locations
United States
Start date
16/09/2026
Identifiers
Trial ID NN9388-8593,
NCT number NCT07817251,
Eudract number Not Available
NCT number NCT07817251,
Eudract number Not Available
Summary
The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.
Trial Overview:
Treatment
DRUG: CagriSema
Study type
INTERVENTIONAL
Trial duration
Sep 16 2026 - Jul 21 2027
Participants
210
Phase
III
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.